Organon & Co. 0A9W.IL Stock
Organon & Co. Price Chart
Organon & Co. 0A9W.IL Financial and Trading Overview
Organon & Co. stock price | 17.58 USD |
Previous Close | 20.85 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 20.85 - 20.85 USD |
52 Week Range | 18.96 - 36.07 USD |
Volume | 7.6K USD |
Avg. Volume | 1.6K USD |
Market Cap | 5.32B USD |
Beta (5Y Monthly) | 0.72007 |
PE Ratio (TTM) | 7.2128024 |
EPS (TTM) | 2.95 USD |
Forward Dividend & Yield | 1.12 (5.53%) |
Ex-Dividend Date | May 12, 2023 |
1y Target Est | N/A |
0A9W.IL Valuation Measures
Enterprise Value | 13.46B USD |
Trailing P/E | 7.2128024 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.86521846 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.19 |
Enterprise Value/EBITDA | 7.53 |
Trading Information
Organon & Co. Stock Price History
Beta (5Y Monthly) | 0.72007 |
52-Week Change | -37.23% |
S&P500 52-Week Change | 20.43% |
52 Week High | 36.07 USD |
52 Week Low | 18.96 USD |
50-Day Moving Average | 21.81 USD |
200-Day Moving Average | 25.36 USD |
0A9W.IL Share Statistics
Avg. Volume (3 month) | 1.6K USD |
Avg. Daily Volume (10-Days) | 804 USD |
Shares Outstanding | 255.06M |
Float | 254.69M |
Short Ratio | N/A |
% Held by Insiders | 0.080% |
% Held by Institutions | 80.05% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 1.12 |
Trailing Annual Dividend Yield | 5.37% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.3836 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 12.14% |
Operating Margin (ttm) | 25.56% |
Gross Margin | 62.50% |
EBITDA Margin | 29.08% |
Management Effectiveness
Return on Assets (ttm) | 9.19% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 6.14B USD |
Revenue Per Share (ttm) | 24.17 USD |
Quarterly Revenue Growth (yoy) | -1.89% |
Gross Profit (ttm) | 3.89B USD |
EBITDA | 1.79B USD |
Net Income Avi to Common (ttm) | 746M USD |
Diluted EPS (ttm) | 2.89 |
Quarterly Earnings Growth (yoy) | -49.10% |
Balance Sheet
Total Cash (mrq) | 459M USD |
Total Cash Per Share (mrq) | 1.8 USD |
Total Debt (mrq) | 8.71B USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.611 |
Book Value Per Share (mrq) | -2.897 |
Cash Flow Statement
Operating Cash Flow (ttm) | 849M USD |
Levered Free Cash Flow (ttm) | 321.25M USD |
Profile of Organon & Co.
Country | United Kingdom |
State | NJ |
City | Jersey City |
Address | 30 Hudson Street |
ZIP | 07302 |
Phone | 551 430 6900 |
Website | https://www.organon.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 10000 |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Q&A For Organon & Co. Stock
What is a current 0A9W.IL stock price?
Organon & Co. 0A9W.IL stock price today per share is 17.58 USD.
How to purchase Organon & Co. stock?
You can buy 0A9W.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Organon & Co.?
The stock symbol or ticker of Organon & Co. is 0A9W.IL.
Which industry does the Organon & Co. company belong to?
The Organon & Co. industry is Drug Manufacturers-General.
How many shares does Organon & Co. have in circulation?
The max supply of Organon & Co. shares is 276.77M.
What is Organon & Co. Price to Earnings Ratio (PE Ratio)?
Organon & Co. PE Ratio is 5.95932200 now.
What was Organon & Co. earnings per share over the trailing 12 months (TTM)?
Organon & Co. EPS is 2.95 USD over the trailing 12 months.
Which sector does the Organon & Co. company belong to?
The Organon & Co. sector is Healthcare.